# Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Source: https://onco.cc/trials/nct07300241/  
OnCo record `nct07300241` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NEO-811 run by Neomorph, Inc, now recruiting.

## Summary

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma is a phase 1 interventional study registered as NCT07300241 by Neomorph, Inc, with 30 participants planned, started 2025-12-19. Conditions recorded: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, Kidney Cancer Metastatic and Kidney Cancers. Interventions recorded: NEO-811.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07300241
- Phase: 1
- Setting: An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- Sponsor: Neomorph, Inc
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07300241: https://clinicaltrials.gov/study/NCT07300241

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [NEO-811](https://onco.cc/drugs/neo-811/)
- companies: [Neomorph](https://onco.cc/companies/neomorph/)

---
JSON: https://onco.cc/api/v1/entities/nct07300241.json